Alzamend Neuro, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for ALZN, updated each market day.
ALZN AI Sentiment
AI predicts Alzamend Neuro, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Alzamend Neuro, Inc. Common Stock
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Sector
Exchange
Market Cap
$3,433,778
Cap Tier
Employees
7
Headquarters
ATLANTA, GA
Listed Since
June 15, 2021
Website
ALZN Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ALZN Volatility
Alzamend Neuro, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
